Role of Occult and Post-acute Phase Replication in Protective Immunity Induced with a Novel Live Attenuated SIV Vaccine
Overview
Authors
Affiliations
In order to evaluate the role of persisting virus replication during occult phase immunisation in the live attenuated SIV vaccine model, a novel SIVmac239Δnef variant (SIVrtTA) genetically engineered to replicate in the presence of doxycycline was evaluated for its ability to protect against wild-type SIVmac239. Indian rhesus macaques were vaccinated either with SIVrtTA or with SIVmac239Δnef. Doxycycline was withdrawn from 4 of 8 SIVrtTA vaccinates before challenge with wild-type virus. Unvaccinated challenge controls exhibited ~107 peak plasma viral RNA copies/ml persisting beyond the acute phase. Six vaccinates, four SIVmac239Δnef and two SIVrtTA vaccinates exhibited complete protection, defined by lack of wild-type viraemia post-challenge and virus-specific PCR analysis of tissues recovered post-mortem, whereas six SIVrtTA vaccinates were protected from high levels of viraemia. Critically, the complete protection in two SIVrtTA vaccinates was associated with enhanced SIVrtTA replication in the immediate post-acute vaccination period but was independent of doxycycline status at the time of challenge. Mutations were identified in the LTR promoter region and rtTA gene that do not affect doxycycline-control but were associated with enhanced post-acute phase replication in protected vaccinates. High frequencies of total circulating CD8+T effector memory cells and a higher total frequency of SIV-specific CD8+ mono and polyfunctional T cells on the day of wild-type challenge were associated with complete protection but these parameters were not predictive of outcome when assessed 130 days after challenge. Moreover, challenge virus-specific Nef CD8+ polyfunctional T cell responses and antigen were detected in tissues post mortem in completely-protected macaques indicating post-challenge control of infection. Within the parameters of the study design, on-going occult-phase replication may not be absolutely required for protective immunity.
Berry N, Mee E, Almond N, Rose N Microorganisms. 2024; 12(1).
PMID: 38257982 PMC: 10818626. DOI: 10.3390/microorganisms12010155.
Stadtmauer E, Sullivan K, El Idrissi M, Salaun B, Alonso Alonso A, Andreadis C Hum Vaccin Immunother. 2021; 17(11):4144-4154.
PMID: 34406911 PMC: 8828160. DOI: 10.1080/21645515.2021.1953346.
Dagnew A, Vink P, Drame M, Willer D, Salaun B, Schuind A Hum Vaccin Immunother. 2021; 17(11):4132-4143.
PMID: 34190658 PMC: 8827627. DOI: 10.1080/21645515.2021.1930846.
Dagnew A, Klein N, Herve C, Kalema G, Di Paolo E, Peterson J J Infect Dis. 2020; 224(7):1139-1146.
PMID: 32103273 PMC: 8514183. DOI: 10.1093/infdis/jiaa083.
Atangana Maze E, Ham C, Kelly J, Ussher L, Almond N, Towers G Front Immunol. 2019; 10:901.
PMID: 31156613 PMC: 6529565. DOI: 10.3389/fimmu.2019.00901.